These results indicated that fisetin suppressed tumor growth in OSCC xenograft models by targeting the MUC1 protein, suggesting fisetin to be a promising therapeutic candidate for OSCC (Fig. 1Z). The gene discussed is MUC1; the disease is neoplasm.